Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elena Ter-Ovanesyan"'
Autor:
Timothy B. Lowinger, Donald A. Bergstrom, Ling Xu, Jian Xu, Dongmei Xiao, Alex Uttard, Elena Ter-Ovanesyan, Cheri A. Stevenson, LiuLiang Qin, Marina Protopova, Laura L. Poling, Peter U. Park, Dennis McGillicuddy, Winnie Lee, Venu R. Gurijala, Dmitry R. Gumerov, Michael J. DeVit, Damon R. Demady, Patrick R. Conlon, Charlie Bu, Mao Yin, Aleksandr V. Yurkovetskiy, Rebecca Mosher, Natalya D. Bodyak
These are figures associated with a second manuscript that has been submitted for consideration for co-publication. It describes the platform and hopefully will facilitate the reviewers' assessment of this manuscript on XMT-1536. we are also happy to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5b872009cdfca855c9f02d87127d20
https://doi.org/10.1158/1535-7163.22522738
https://doi.org/10.1158/1535-7163.22522738
Autor:
Timothy B. Lowinger, Donald A. Bergstrom, Ling Xu, Jian Xu, Dongmei Xiao, Alex Uttard, Elena Ter-Ovanesyan, Cheri A. Stevenson, LiuLiang Qin, Marina Protopova, Laura L. Poling, Peter U. Park, Dennis McGillicuddy, Winnie Lee, Venu R. Gurijala, Dmitry R. Gumerov, Michael J. DeVit, Damon R. Demady, Patrick R. Conlon, Charlie Bu, Mao Yin, Aleksandr V. Yurkovetskiy, Rebecca Mosher, Natalya D. Bodyak
These are figures associated with a second manuscript that has been submitted for consideration for co-publication. It describes the platform and hopefully will facilitate the reviewers' assessment of this manuscript on XMT-1536. we are happy to make
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7da7268afac65c3294d060c5e6c69b
https://doi.org/10.1158/1535-7163.22522741
https://doi.org/10.1158/1535-7163.22522741
Autor:
Timothy B. Lowinger, Donald A. Bergstrom, Peter U. Park, Qingxiu Zhang, Ling Xu, Marina Protopopova, Laura L. Poling, Michael J. DeVit, Dennis McGillicuddy, Venu R. Gurijala, Alex J. Johnson, Charlie Bu, Elena Ter-Ovanesyan, Dmitry R. Gumerov, LiuLiang Qin, Alex Uttard, Cheri A. Stevenson, Patrick R. Conlon, Susan M. Clardy, Joshua D. Thomas, Mao Yin, Natalya D. Bodyak, Aleksandr V. Yurkovetskiy
Supplementary methods, data and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650945d96b4cb4ca36cc61fe8daa399d
https://doi.org/10.1158/1535-7163.22522479
https://doi.org/10.1158/1535-7163.22522479
Autor:
Timothy B. Lowinger, Donald A. Bergstrom, Ling Xu, Jian Xu, Dongmei Xiao, Alex Uttard, Elena Ter-Ovanesyan, Cheri A. Stevenson, LiuLiang Qin, Marina Protopova, Laura L. Poling, Peter U. Park, Dennis McGillicuddy, Winnie Lee, Venu R. Gurijala, Dmitry R. Gumerov, Michael J. DeVit, Damon R. Demady, Patrick R. Conlon, Charlie Bu, Mao Yin, Aleksandr V. Yurkovetskiy, Rebecca Mosher, Natalya D. Bodyak
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f84d8d23561ce01710afb14c790013
https://doi.org/10.1158/1535-7163.22522732
https://doi.org/10.1158/1535-7163.22522732
Autor:
Timothy B. Lowinger, Donald A. Bergstrom, Peter U. Park, Qingxiu Zhang, Ling Xu, Marina Protopopova, Laura L. Poling, Michael J. DeVit, Dennis McGillicuddy, Venu R. Gurijala, Alex J. Johnson, Charlie Bu, Elena Ter-Ovanesyan, Dmitry R. Gumerov, LiuLiang Qin, Alex Uttard, Cheri A. Stevenson, Patrick R. Conlon, Susan M. Clardy, Joshua D. Thomas, Mao Yin, Natalya D. Bodyak, Aleksandr V. Yurkovetskiy
After significant effort over the last 30 years, antibody–drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date, with additional ADCs in late stages of development. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951b8c25dbbe73e1c85ae90ec75bc178
https://doi.org/10.1158/1535-7163.c.6543396
https://doi.org/10.1158/1535-7163.c.6543396
Autor:
Timothy B. Lowinger, Alex Uttard, Elena Ter-Ovanesyan, Dmitry R. Gumerov, Bangmin Zhu, LiuLiang Qin, Charles E. Hammond, Joshua D. Thomas, Cheri A. Stevenson, Natalya Bodyak, Mao Yin, Alexander V. Yurkovetskiy
Sensorgrams of trastuzumab-PHF-vinca binding the hErbB2 surfaces, ~420 RU (top) and ~1320 RU (bottom).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7346018cea49c71d286608b271914152
https://doi.org/10.1158/0008-5472.22405691.v1
https://doi.org/10.1158/0008-5472.22405691.v1
Autor:
Timothy B. Lowinger, Alex Uttard, Elena Ter-Ovanesyan, Dmitry R. Gumerov, Bangmin Zhu, LiuLiang Qin, Charles E. Hammond, Joshua D. Thomas, Cheri A. Stevenson, Natalya Bodyak, Mao Yin, Alexander V. Yurkovetskiy
Sensorgrams of trastuzumab binding the hErbB2 surfaces, ~420 RU (top) and ~1320 RU (bottom).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2687560fc04246aa43b16b79c3d25621
https://doi.org/10.1158/0008-5472.22405694.v1
https://doi.org/10.1158/0008-5472.22405694.v1
Autor:
Timothy B. Lowinger, Alex Uttard, Elena Ter-Ovanesyan, Dmitry R. Gumerov, Bangmin Zhu, LiuLiang Qin, Charles E. Hammond, Joshua D. Thomas, Cheri A. Stevenson, Natalya Bodyak, Mao Yin, Alexander V. Yurkovetskiy
Synthesis of HPV-Ala-NH2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b69b91b6caba3f900733482b3cb7c29
https://doi.org/10.1158/0008-5472.22405697.v1
https://doi.org/10.1158/0008-5472.22405697.v1
Autor:
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Lancaster, Keith W. Bentley, Suzanna Clark, Susan Clardy, Scott D. Collins, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Eugene W. Kelleher, Travis Monnell, Marina Protopopova, Caitlin Routhier, Cheri Stevenson, Elena Ter-Ovanesyan, Joshua D. Thomas, Alex Uttard, Jason Wang, Phonphimon Wongthida, Ling Xu, Annika Yau, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Publikováno v:
Cancer Research. 82:3503-3503
We present here a novel therapeutic agent, XMT-2056, that results in robust anti-tumor activity mediated by an immune response through targeted delivery of a STING agonist to the tumor microenvironment. By leveraging an antibody-drug conjugate (ADC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0104b7acc0fcee8f20a6655acfc9a034
https://doi.org/10.1158/1538-7445.am2022-3503
https://doi.org/10.1158/1538-7445.am2022-3503
Autor:
Donald A. Bergstrom, Cheri A. Stevenson, Venu R. Gurijala, Ling Xu, Dongmei Xiao, Timothy B. Lowinger, Mao Yin, Jian Xu, Aleksandr V. Yurkovetskiy, Peter U. Park, Winnie Lee, Patrick R. Conlon, Charlie Bu, Dennis McGillicuddy, Damon R. Demady, Rebecca Mosher, Elena Ter-Ovanesyan, Laura L. Poling, Michael J. DeVit, Alex Uttard, Natalya D. Bodyak, Dmitry R. Gumerov, Marina Protopova, LiuLiang Qin
Publikováno v:
Molecular cancer therapeutics. 20(5)
Target selection for antibody–drug conjugates (ADC) frequently focuses on identifying antigens with differential expression in tumor and normal tissue, to mitigate the risk of on-target toxicity. However, this strategy restricts the possible target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c97f519956a37e7d6ea447a76acbecb
https://pubmed.ncbi.nlm.nih.gov/33722858
https://pubmed.ncbi.nlm.nih.gov/33722858